Interchangeable Biosimilar Approval: FDA Greenl...

By João L. Carapinha

November 17, 2025

FDA Grants First Interchangeable Biosimilar Approval for HER2-Positive Breast Cancer Treatment The U.S. Food and Drug Administration (FDA...
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
FDA Cancer Trial Guidelines: Prioritizing Overall Survival for Patient-Center...
Keytruda Lung Cancer Treatment: Long-Term Survival Gains in NSCLC
Promising PSMA-Targeted Therapy Delays Prostate Cancer Progression
Johnson & Johnson Advances Solid Tumor Research at ESMO 2025 with Promis...
Colorectal Cancer Markers: Discovering Region-Specific Drivers for Precision ...
Tukysa Breast Cancer Therapy Boosts Progression-Free Survival in Advanced Cases
Datroway TNBC Therapy: Transforming First-Line Treatment for Metastatic Tripl...
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications
Enhertu Breast Cancer Treatment: Major Advances in Invasive Disease-Free Surv...
Transforming Cancer Treatment: Implications of Subcutaneous Pembrolizumab App...